ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / APYX / forecast
PYPD (41) SKYA (43) LUNG (38) NYXH (45) ⌘ Pro Terminal →

Apyx Medical Corporation (APYX) 12-Month Stock Forecast & Price Target Cone

$2.60 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.60

Apyx Medical Corporation (APYX) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $109.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APYX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.60 (0.00% 1D, market cap $109.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, APYX ranks #970 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APYX compare to PYPD and SKYA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $109.5M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APYX?
▼

Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.60 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510021
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (4)Whales (5)SEC (6)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.5% Base Target
$5 Bull$2 Base$2 Bear
📬 FREE APYX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APYX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (21/100 Composite)
🔍 WHY APYX SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)

Altman Z-Score 0.75 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$2.65-8.7% Next Q
Q2 (-2Q)
26
Grade E$2.42+1.7% Next Q
Q3 (-1Q)
24
Grade E$2.46+5.7% Next Q
Current
21
Grade E$2.60-11.6% Hist 90D α
Trajectory: E (29) → E (21)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APYX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APYX currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.76) and Max Pain ($2.73) forces dealer call-delta covering toward $5.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APYX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “APYX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 21%NO 79%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your APYX Position Size: $10,000

Shares at $2.60: 3846.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.69
$6,500
$-3,500 (-35.0%)
12M Consensus BaseTarget $2.17
$8,346
$-1,654 (-16.5%)
12M Bull Case BreakoutTarget $5.33
$20,500
+$10,500 (+105.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$569%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APYX)

  • ✓Walkthrough of APYX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
APYX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.77%⚡ TESTING RESISTANCE
2026-11-03O $2.69H $2.69L $2.60C $2.60VOL 38.1K
RES: $2.63SUP: $1.87SMA50: $2.76SMA200: $3.59
$5.28$4.46$3.64$2.82$2.00RES $2.63SUP $1.87$2.602026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APYX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APYX Butterfly Map → + Track APYX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on APYX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APYX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for APYX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APYX)

Health Care Rank #970 of 1015 ⚔️ PYPD vs APYX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APYX vs. PYPD, SKYA, LUNG, NYXH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Apyx Medical Corporation (APYX) ranks #970 by composite RQD confidence (21/100, grade E) and #638 by equity capitalization ($109.5M). Within this direct 5-issuer industry benchmark cohort, APYX leads on earnings valuation at N/A trailing P/E, while APYX leads on capital efficiency and profitability with -28.9% ROIC and 62.5% gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with APYX at 21/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
APYX ACTIVE
Apyx Medical Corporation
E 21/100 — 62.5% -28.9% 0.00% $109.5M Benchmark Subject
PYPD
PolyPid Ltd.
D- 41/100 — — -35.0% +0.56% $109.5M /pypd-vs-apyx →
SKYA
SkyAI Inc.
D- 43/100 — -30.0% -35.0% -1.35% $128.4M /skya-vs-apyx →
LUNG
Pulmonx Corporation
D- 38/100 — 74.2% -35.0% -14.14% $129.1M /lung-vs-apyx →
NYXH
Nyxoah SA
D 45/100 — — — +0.99% $87.2M /nyxh-vs-apyx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000719135 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apyx Medical Corporation (APYX) reported GAAP revenue of $52.8M (+9.9% vs. FY2024 revenue of $48.1M , and +0.9% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of -$8.0M, and free cash flow of -$9.1M (+51.4% YoY). On the balance sheet, APYX closed FY2025 with $66.8M in total assets against $34.8M in total debt (Altman Z-Score: 0.75, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $52.8M -$11.2M -$8.0M -$9.1M $66.8M $34.8M
FY2024 (FY) 2024-12-31 $48.1M -$23.5M -$18.0M -$18.8M $64.8M $33.9M
FY2023 (FY) 2023-12-31 $52.3M -$18.7M -$5.2M -$5.2M — —

3. APYX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.60 (0.00% 1D, market cap $109.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, APYX ranks #970 in composite RQD confidence.

How does APYX compare to PYPD and SKYA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $109.5M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APYX?

Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APYX trading relative to its 50-day, 200-day, and 52-week technical levels?

APYX last traded at $2.60 (0.00% on volume of 116,205 shares), positioning the stock -5.80% below its 50-day simple moving average ($2.76) and -27.58% below its 200-day simple moving average ($3.59). Across its 52-week range of $2.25 to $5.08, APYX sits at the 12.4% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.27 to $2.93).

Direct Sub-Reports: APYX RQD Cockpit APYX 12M Forecast APYX Earnings & Move APYX Dividends & DRIP APYX Insiders & 13F APYX Whale Options APYX Profit Sankey APYX News & Why
ROARABLE RATING BRIEF • RQD 21/100 (E) ✓ SEC XBRL & RQD VERIFIED

APYX — Apyx Medical Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Apyx Medical Corporation (APYX) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.60 (0.00% 1D, market capitalization $109.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -28.9%, gross margin of 62.5%, operating margin of -12.2%, and free cash flow yield of -8.04%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.75, Piotroski F-Score of 5/9, and Debt/Equity of 2.40x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Apyx Medical Corporation (NASDAQ: APYX) is classified in the Health Care sector and the Medical/Dental Instruments industry .8M for FY 2025 indicates an operating business of meaningful scale.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Apyx Medical Corporation (APYX) reported $52.8M in annual revenue (up from $48.1M in FY2024, +9.9% YoY) and -$11.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($52.3M revenue, -$18.7M net income) through FY2025, APYX scaled operating cash flow to -$8.0M and free cash flow to -$9.1M, backed by $66.8M in total assets against $34.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 21/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.04% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.25 – $5.08 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -12.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links are recorded and no proprietary signals are listed, so no supply-chain dependencies can be mapped from the source data. The sector classification (Health Care) and industry (Medical/Dental Instruments) are the only sector context provided. Sector correlation data is — An investor should watch the November 5, 2026 Q3 results as the first hard data point on whether the reported losses are narrowing, since the source data contains no supply-chain bottleneck information.

  • Key Question #1: Can APYX sustain or expand its -12.2% operating margin and -28.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $52.8M and free cash flow of -$9.1M, how will capital allocation balance growth reinvestment against $34.8M in total debt?
  • Key Question #3: How sensitive is APYX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

APYX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Apyx Medical Corporation (APYX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APYX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APYX Bull vs. Bear Conversation Board — What's Your Call at $2.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APYX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on APYX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $3.43 (+31.9%)
📌 Pinned Debate

Institutional accumulation and options positioning contribute 12/20 to the RQD score, the strongest pillar relative to the others.

Long APYX at $2.60 targeting $3.43. Institutional accumulation and options positioning contribute 12/20 to the RQD score, the strongest pillar relative to the others.. Institutional whale score is 5/20 and the risk/reward vs. the $2.25 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (62.5%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $2.21 (-15.0%)
Spot @ $2.60

ROIC of -28.9% and FCF yield of -8.04% leave the Fundamental Cash Engine at 4/20 with an Altman Z of 0.75.

Here is the bear case nobody on the bull side wants to address on APYX: ROIC of -28.9% and FCF yield of -8.04% leave the Fundamental Cash Engine at 4/20 with an Altman Z of 0.75.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE